Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2012 | 02:00pm CEST

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
08:46a STILLFRONT GROUP AB : Stillfront Interim Report January - June 2016
08:46a RAK PETROLEUM : Releases Half-Year Financial Report for the Period Ended 30 June 2016
08:46a TOSHIBA : Launches Low-Input Current Drive, Rail-to-Rail Output, Gate-Drive Photocouplers
08:45a FLAT GLASS : to raise up to Rmb1.84bn from A share issue
08:45a DAOHE GLOBAL : to consolidate shares on 10-to-1 basis
08:45a HYDOO INTERNATIONAL : Int'l to issue US$60m senior notes
08:45a India's Infosys says seeing client-specific softness after Brexit
08:45a Dyesol Ltd Annual Report 2016 to Shareholders
08:44a SALTANGEN PROPERTY INVEST PUBL : Interim Report 1 January 2016 - 30 June 2016 Saltängen Property Invest
08:44a RTX A/S : Announcement 58-2016
Latest news
Advertisement
Hot News 
0.62%GROWTHPOINT (ASX : GOZ) talks FY16 results and outlook
-0.32%Crude Oil Prices Rise on OPEC Deal Hopes, Yellen Threatens Gold
-1.13%NIKKEI 225 TECHNICAL ANALYSIS : Edging Lower to Close a Quiet Week
Most Read News
12:48a Lotte Group vice chairman found dead, suicide suspected
08/25 VOLKSWAGEN : to spend at least $1.2 billion to compensate U.S. dealers - sources
08/25 APPLE : fixes security flaw after UAE dissident's iPhone targeted
08/25 GENERAL MOTORS : GM cleared in second U.S. verdict over crash blamed on ignition switch
08/25 ALLIANZ : Austria's Heta says winding down of assets progressing well
Most recommended articles
02:44a INFOSYS : India's Infosys says seeing client-specific softness after Brexit
02:42a Taiwan's CTBC Financial, China CITIC Bank cancel deals
02:20a GROWTHPOINT (ASX : GOZ) talks FY16 results and outlook
02:18a British economy escapes Brexit 'bomb', for now
02:16aDJSABMILLER : Scheme of arrangement -4-